Driehaus Capital Management LLC Aeglea Bio Therapeutics, Inc. Transaction History

Driehaus Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.11 - $0.46 $510,769 - $2.14 Million	4,643,357 New	4,643,357 $2.09 Million
Q2 2021 Aug 16, 2021	SELL	$6.32 - $8.38 $1.11 Million - $1.47 Million	-175,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$6.76 - $8.57 $1.63 Million - $2.07 Million	-241,266 Reduced 57.96%	175,000 $1.39 Million
Q4 2020 Feb 16, 2021	SELL	$7.02 - $9.83 $41,425 - $58,006	-5,901 Reduced 1.4%	416,266 $3.28 Million
Q3 2020 Nov 16, 2020	SELL	$6.51 - $9.33 $48,968 - $70,180	-7,522 Reduced 1.75%	422,167 $2.99 Million
Q2 2020 Aug 14, 2020	BUY	$4.01 - $11.04 $1.72 Million - $4.74 Million	429,689 New	429,689 $3.98 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Driehaus Capital Management LLC with notifications on news.